Raleigh, NC – According to filings with the U.S. Securities and Exchange Commission, Gemelli Biotech is raising $19,967,887.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Matthew Mitcho played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Gemelli Biotech
Gemelli Biotech is a specialty biotechnology company that strives to achieve a thriving global family of healthy individuals by unlocking the potential of the microbiome. Gemellis mission is to support the discovery of novel diagnostics and therapeutics for the human microbiome by bringing biotechnology innovations to market in a fiscally responsible and socially conscious way. Gemelli Biotech is proud to partner closely with Cedars-Sinai in Los Angeles, ranked by US News and World Report as one of the top 10 hospitals in the nation. The Medically Associated Science and Technology (MAST) program at Cedars-Sinai is dedicated to the development of microbiome diagnostics and therapeutics and works closely with Gemelli. Alignment with MAST allows Gemelli to operate on the cutting edge, with an early look at the newest scientific discoveries related to the microbiome.

To learn more about Gemelli Biotech, visit http://www.gemellibiotech.com/

Contact:
Matthew Mitcho, Chief Executive Officer
919-451-0533
https://www.linkedin.com/in/matt-mitcho-9a522b2/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved